The CDC recommends providers counsel gay, bisexual, MSM, and transgender women about using doxycycline for post-exposure prophylaxis (doxy-PEP) to prevent sexually transmitted infections (STIs). This recommendation is based on evidence showing the effectiveness of doxy-PEP in reducing the risk of acquiring chlamydia and syphilis. The CDC advises offering doxy-PEP to patients with a history of STIs within the past 12 months and assessing the ongoing need for the medication every 3 to 6 months. While the evidence supports its use in certain populations, recommendations for other groups are not provided due to insufficient data. The guidelines will be updated as more data becomes available.
Source link
CDC recommends clinicians counsel certain patients about doxy-PEP for STI prevention
